.Pharmacolibrary.Drugs.ATC.L.L01FX28 .Pharmacolibrary.Drugs.ATC.L.L01FX28| name: | Glofitamab | |
| ATC code: | L01FX28 | |
| route: | intravenous | |
| compartments: | 2 | |
| dosage: | 30 | mg |
| volume of distribution: | 3.6 | L |
| clearance: | 0.25 | L/day |
| other parameters in model implementation | ||
Glofitamab is a humanized, bispecific CD20-directed CD3 T-cell engager antibody used for the treatment of B-cell non-Hodgkin’s lymphoma. It induces T-cell mediated cytotoxicity of malignant B cells. Glofitamab was approved by the FDA in 2023 under the trade name Columvi.
Pharmacokinetic parameters in adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma following intravenous administration.